Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited

References

• Schafer JJ, Goff DA. Establishing the role of tigecycline in an era of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(5):557–567.
   PubMed Web of Science ®Google Scholar
• Wyeth Pharmaceutics. Tygacil (tigecycline) for injection [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2005.
   Google Scholar
• Pankey GA. Tigecycline. J Antimicrob Chemo. 2005;56:470–480.
   PubMed Web of Science ®Google Scholar
• Doan TL, Fung HB, Mehta D, et al. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006;28(8):1079–1106.
   PubMed Web of Science ®Google Scholar
• Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;42(4):518–524.
   PubMed Web of Science ®Google Scholar
• Kasbekar N. Tigecycline: a new glyclcycline antimicrobial agent. Am J Health Syst Pharm. 2006;63(13):1235–1243.
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro activity of tigecycline against 3989 gram negative and gram positive clinical isolates from the United States tigecycline evaluation and surveillance trial. Diagn Microbiol Infect Dis. 2005;52(3):173–179.
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699–1709.
   PubMed Web of Science ®Google Scholar
• Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother. 2005;17(Suppl 1):12–22.
   PubMed Web of Science ®Google Scholar
• Zarkotou A, Pournaras S, Altouvas G, et al. Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin and carbapenem resistant gram negative pathogens. J Clin Microbiol. 2012;10:3747–3750.
   Web of Science ®Google Scholar
• Cunha BA. Problems arising in antimicrobial therapy due to false susceptibility testing. J Chemother. 1997;9(1):25–35.
   PubMed Web of Science ®Google Scholar
• Idelevich EA, Busing M, Mischnik A, et al. False non-susceptible results of tigecycline susceptibility testing against enterobacteriacae by an automated system: a multicenter study. J Med Microbiol. 2016;65(8):877–881.
   PubMed Web of Science ®Google Scholar
• Casal M, Rodriguez F, Johnson B, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible acinetobacter spp. J Antimicrob Chemother. 2009;64(1):69–72.
   PubMed Web of Science ®Google Scholar
• Hope R, Mushtaq S, James D, et al. Tigecycline activity: low resistance rates but problematic disc breakpoints reaveled by a multicenter sentinel survey in the UK. J Antimicrob Chemother. 2010;6(12):2602–2609.
   Web of Science ®Google Scholar
• Woodford N, Hill RL, Livermore DM. In vitro activity of tigecycline against carbapenem-susceptible and resistant isolates of klebsiella spp. and enterobacter spp. J Antimicrob Chemother. 2007;59(3):582–583.
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. Jantimicrob Chemother. 2008;62(Suppl 1):i11–16.
   PubMed Web of Science ®Google Scholar
• Sevillano D, Aguilar L, Alou L, et al. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Int J Antimicrob Agents. 2010;36(2):137–144.
   PubMed Web of Science ®Google Scholar
• Peterson LR. Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline. Diagn Microbiol Infect Dis. 2005;52(3):163–164.
   PubMed Web of Science ®Google Scholar
• Cunha BA. Tigecycline dosing is critical in preventing tigecycline resistance because relative resistance is, in part, concentration dependent. Clinical microbiology and infection. Clin Microbiol Infect. 2015;21(5):e39–40.
   PubMedGoogle Scholar
• Cunha BA. Effective antibiotic resistance control strategies. Lancet. 2001;357(9265):1307–1308.
   PubMed Web of Science ®Google Scholar
• Di carlo P, Gulotta G, Casuccio A, et al. KPC - 3 klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol. 2013;13(1):13.
   PubMed Web of Science ®Google Scholar
• Xu L, Wang YL, Du S, et al. Safety of tigecycline for patients with hospital-acquired pneumonia. Chemotherapy. 2016;61(6):323–330.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Kelesidis T, Dien Bard J, et al. Successful treatment of pan-resistant klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. J Medmicrobiol. 2010;59:1383–1386.
   Web of Science ®Google Scholar
• Dandache P, Nicolau DP, Sakoulas G. Tigecycline for the treatment of multidrug-resistant klebsiella pneumoniae meningitis. Infect Dis Clinpractice. 2009;17(1):66–68.
   Google Scholar
• Ray L, Levasseur K, Nicalau DP, et al. Cerebral spinal fluid penetration of tigecycline in a patient with acinetobacter baumannii cerebritis. Ann Pharmacother. 2010;44(3):582–586.
   PubMed Web of Science ®Google Scholar
• Conte JE, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25(6):523–529.
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamics profile of tigecycline. Clin Infect Dis. 2005;41(Suppl5):S333–S340.
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):220–229.
   PubMed Web of Science ®Google Scholar
• Xie J, Wang T, Sun J, et al. Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by monte carlo simulation. Int J Infect Dis. 2014;18:62–67.
   PubMed Web of Science ®Google Scholar
• Cunha BA. Antibiotic Essentials (14th Ed.). JayPee Medical Publishers. New Delhi; 2015. p. 700–701.
   Google Scholar
• Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. Clinical microbiology and infection. Clin Microbiol Infect. 2000;6(5):270–273.
   PubMed Web of Science ®Google Scholar
• Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias. J Chemother. 2007;19(2):232–233.
   PubMed Web of Science ®Google Scholar
• Cunha BA, McDermott B, Nausheen S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) klebsiella pneumoniae and enterobacter aerogenes nosocomial urinary tract infection. J Chemother. 2007;19(6):753–754.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mendler MH, Hemming AW, et al. High-dose tigecycline and colistin for successful treatment of disseminated carbapenem-resistant Klebsiella pneumoniae infection in a liver transplant recipient. BMJ Case Rep. 2014;5:1-4.
   Google Scholar
• Brust K, Evans A, Plemmons R. Favourable outcome in the treatment of carbapenem-resistant enterobacteriaceae urinary tract infection with high-dose tigecycline. J Antimicrob Chemother. 2014;69(10):2875–2876.
   PubMed Web of Science ®Google Scholar
• Sbrana F, Malacarne P, Viaggi B, et al. Carbapenem-sparing antibiotic regimens for infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis. 2013;56(5):697–700.
   PubMed Web of Science ®Google Scholar
• Balandin Moreno B, Fernandez Simon I, Pintado Garcia V, et al. Tigecycline therapy for infections due to carbapenemase-producing klebsiella pneumoniae in critically ill patients. Scand J Infect Dis. 2014;46(3):175–180.
   PubMed Web of Science ®Google Scholar
• De pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Critical Care (London). 2014;18(3):R90.
   PubMed Web of Science ®Google Scholar
• Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756–1762.
   PubMed Web of Science ®Google Scholar
• Baron J, Cai S, Klein N, et al. High Dose Once Daily Tigecycline is Optimal: tigecycline Dosing Regimens Determine Clinical Effectiveness. J Clin Pham Therap. 2016;27. In press.
   Google Scholar
• Burkhardt O, Rauch K, Kaever V, et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int Jantimicrob Agents. 2009;34(1):101–102.
   PubMed Web of Science ®Google Scholar
• Gamacho-Montero J. Ferandiz-Milon C high dose of tigecycline for extremely resistant gram-negative pneumonia: yes, we can. Crit Care. 2014;18(3):157.
   PubMed Web of Science ®Google Scholar
• Poulakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect. 2009;58(4):273–284.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Kelesidis T, Kelesidis I, et al. Tigecycline for the treatment of multidrug-reistant (including carbapenem-resistant acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother. 2008;61(1):45–55.
   Web of Science ®Google Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother. 2005;56(4):611–614.
   PubMed Web of Science ®Google Scholar
• Hung YP, Lee JC, Lin HJ, et al. Doxycycline and tigecycline: two friendly drugs with a low association with clostridium difficile infection. Antibiotics. 2015;4(2):216–229.
   Web of Science ®Google Scholar
• Cheong EY, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent clostridium difficile colitis. Med J Aust. 2011;194(7):374–375.
   PubMed Web of Science ®Google Scholar
• Thomas A, Khan F, Uddin N, et al. Tigecycline for severe clostridium difficile infection. Int J Infect Dis. 2014;26:171–172.
   PubMed Web of Science ®Google Scholar
• Parker SL, Sime FB, Roberts JA. Optimizing dosing of antibiotics in critically ill patients. Curr Opin Infect Dis. 2015;28(6):497–504.
   PubMed Web of Science ®Google Scholar
• Routsi C, Kokkoris S, Douka E, et al. High-dose tigecycline associated alterations in coagulation parameters in critically ill patients with severe infections. Int Jantimicrob Agents. 2015;45:84–85.
   PubMed Web of Science ®Google Scholar